You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新股暗盤 | 亞盛醫藥-B(6855.HK)暗盤段大漲逾30%
格隆匯 10-25 16:23
格隆匯10月25日丨據輝立證券,亞盛醫藥-B(6855.HK)暗盤段大漲,現報46.05港元較發行價34.2港元漲34.6%。

公司為一間放眼全球的臨牀階段生物科技公司,從事開發治療癌症、乙型肝炎病毒(HBV)及衰老相關疾病的新型療法;在研產品包括新型小分子候選藥物。該等候選藥物可破壞複雜且難以標靶的蛋白-蛋白相互作用(PPI),以及下一代酪氨酸激酶抑制劑(TKI)。
公司2016年至2018年收益分別為766.7萬、632.8萬、680.7萬元人民幣,此次全球發售約1218.09萬股,其中香港發售609.05萬股,國際發售609.04萬股,每手100股,淨籌約3.12億港元;香港公開發售獲751.99倍超額認購,中國生物製藥作為基石投資者已確定認購458.64萬股(即全球發售初步可供認購發售股份的約37.65%,完成發行後總額的2.21%)。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account